By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Drug Manufacturers - General
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Institution %: 80.792
YTD Institution change: 6252153
InsidersInsiders %: 0.157
Insiders Purchases YTD: 2720
Insiders Sales YTD:
Insiders Net YTD: 2720
Analyst RatingsTarget Price: 29.29
Overall Rating: 3.4444
Strong Buys (5): 1
Buys (4): 3
Holds (3): 4
Sells (2): 1
Strong Sells (1): 0
52 Week Hi: 22.5397
52 Week Low: 10.5257
Beta: 0.811
50 Day MA: 20.9122
200 Day MA: 17.2403
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0.13
Qtr Revenue Growth YOY: 0.055
Forward PE:
Trailing PE: